Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...

Moderna Inc. recorded a quarterly loss as vaccine sales waned and the company had an unexpected charge for a canceled ...

the best-selling drug in the world, to decline in the coming years? And can they trust Merck’s guidance on that decline? The problems with Gardasil relate entirely to sales of the vaccine in ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

This update provides insights into critical global health developments, including Merck's halt on Gardasil shipments to China ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Merck's lead drug, Keytruda, grew sales by 19% last year ... it recently raised to $1.72 per share. Sales of Pfizer's COVID-19 treatment and vaccine are down a long way from their peak, but ...

Its monotherapy drug that is used to treat desmoid tumors has been approved in the United States. A transaction for Springworks would rank as one of the biggest pharma deals for Merck in recent ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its Covid business and stock price.

The company’s inability to accurately project demand for its Covid-19 products sent its ... growth in its weight-loss and diabetes drugs. Now it is Merck & Co. under the microscope.